Ignite Creation Date:
2024-05-06 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631706
Status:
COMPLETED
Last Update Posted:
2024-02-26
First Post:
2018-08-09
Brief Title:
M7824 Versus Pembrolizumab as a First-line 1L Treatment in Participants With Programmed Death-ligand 1 PD-L1 Expressing Advanced Non-small Cell Lung Cancer NSCLC
Sponsor:
Organization:
EMD Serono